Industry Insider News

Amniox Earns Supply Contract With U.S. Military

Officials at Amniox Medical Inc., a TissueTech Inc. company based in Atlanta, GA, have announced a new federal supply schedule contract for the NEOX^® and CLARIX^® product lines. The agreement provides the Military Health System, the enterprise within the United States Department of Defense that provides healthcare to active duty and retired U.S. military personnel and their dependents, with broad access to NEOX Wound Allograft (a product indicated for use as a wound covering for dermal ulcers and defects) and CLARIX Regenerative Matrix (indicated for use as a surgical covering, wrap, or barrier in orthopedic surgery and soft tissue repair), officials said.

Military Health System reportedly provides healthcare coverage to 10.2 million people. Amniox Medical is partnering exclusively with Alliant Healthcare Products, a verified service-disabled and veteran-owned small business located in Grand Rapids, MI

“We are pleased to increase the availability of our unique technologies for the nation’s veterans and active-duty military patients, and the clinicians who deliver care to them,” said Tom Dugan, chief executive officer of Amniox. “Acknowledgement of the clinical benefits that our proprietary technology offers to patients continues to deepen among providers and payers, now including broad accessibility this very important patient population through this contract.”

Amniox Medical is the first provider of a human tissue allograft composed of both umbilical cord and amniotic membrane, officials said. The biological components of these tissues have demonstrated regenerative properties that can provide healing benefits to patients living with numerous medical conditions. For more information, visit www.amnioxmedical.com

ETS Wound Care Rolls Out New Technology

ETS Wound Care LLC, a privately held medical device company based in Rolla, MO, has released MIRRAGEN^TM Advanced Wound Matrix, a glass-based wound care product that emerged from research by a doctoral student and has been approved by the U.S. Food & Drug Administration (FDA) for human use to treat acute and chronic wounds.

According to a report by The Rolla Daily News, Steve Jung, PhD, conceived the product while earning a master’s degree in ceramic engineering and a doctorate in materials science and engineering at Missouri University of Science & Technology. ETS developed the product in collaboration with Mo-Sci Corp., a Rolla-based specialty glass manufacturer where Jung serves as chief technology officer.

According to the report, ETS, a subsidiary of Engineered Tissue Solutions LLC, plans for a controlled domestic market release of Mirragen while making the product available to the broader domestic market in 2018.

“The recent FDA approval is a significant milestone for ETS,” said Chad Lewis, PhD, chief executive officer and president at ETS Wound Care. “ETS Wound Care is pioneering an entirely new therapeutic option for wound care. The MIRRAGEN Advanced Wound Matrix is the first product utilizing our innovative borate fiber technology engineered to improve patient outcomes.”

According to ETS officials, MIRRAGEN is based on a resorbable and biocompatible borate-based bioactive glass specifically designed for wound healing. The material will slowly dissolve upon exposure to body fluid. As the borate glass dissolves, it releases ions at the wound site. Following dressing changes, any borate material remaining at the wound site is absorbed by the surrounding tissue. For more information, visit www.etswoundcare.com

Rehab Company Acquires Wound Care Specialists

Officials at Rehab Medical Inc., an Indianapolis-based company that provides physical medicine and rehabilitation equipment, have announced the acquisition of Ohio-based Crow Creek Therapeutics, a medical company in the wound care industry. Financial details of the deal were not disclosed, according to Inside Indiana Business. The transaction is expected to result in a launch of a high-quality wound care division with the expectation of growing the Indianapolis headquarters, the report claims. Crow Creek provides wound care therapy and support to patients in Ohio and Michigan. Employees will reportedly continue to serve those patients. Rehab Medical provides services in more than 20 major metropolitan markets throughout the country. About 20 new jobs are anticipated. For more information, visit www.rehabmedical.com

Brindle Named VP of Clinical Affairs By IHT Technologies

Integrated Healing Technologies (IHT), a negative pressure wound therapy (NPWT) and advanced wound care company based in Franklin, TN, has named Tod Brindle, PhD-c, MSN, RN, CWOCN, as vice president of clinical affairs. Brindle will be responsible for all clinical functions within the company, according to officials.

Brindle served as the nurse clinician and clinical administrator with the wound care team at Virginia Commonwealth University Medical Center (VCUMC) for 12 years.  Prior to his position at VCU Health, he served in various roles at multiple prestigious institutions across the country. He earned his bachelor’s degree from Ohio State University and graduated from the R.B. Turnbull School of Enterostomal Therapy Nursing at the Cleveland Clinic School of Medicine as an enterostomal therapy nurse. He holds a master’s of science in nursing, administration and leadership from VCU and is completing a PhD in nursing with a focus on lipidomic expression of oxidative stress in deep tissue injuries from VCU.

The American Nurses Credentialing Center (ANCC) Magnet National Nurse of the Year in 2013, Brindle has also served on the board of directors for the Association for the Advancement of Wound Care, the ANCC Magnet Commission, and is a co-chair of the wound track for the national conference planning committee of the Wound, Ostomy and Continence Nurses Society.

"Tod brings tremendous clinical experience and expertise to our leadership team," said Pete Carino, executive vice president and chief sales officer of IHT. "He will lead our clinical team to help us bring new technologies and deliver innovative products and solutions to the advanced wound care and [NPWT] market; helping patients and clinicians alike. Tod's leadership will allow us to rapidly grow market share. Patients, caregivers, and providers are looking for wound healing therapies that can improve quality of care while reducing healthcare costs. [IHT] puts these principles at the foundation of every product and solution we offer.”